

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/M52D4463D1B6EN.html>

Date: September 2022

Pages: 47

Price: US\$ 2,000.00 (Single User License)

ID: M52D4463D1B6EN

Abstracts

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drugs In Development, 2022, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline landscape.

Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease),

complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 1, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of

development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved
in Therapeutics Development

Basilea Pharmaceutica Ltd

BioPlx Microbiomics Pvt Ltd

Debiopharm International SA

Destiny Pharma Plc

HyPharm GmbH

LegoChem Biosciences Inc

Naicons Srl

Pharma Holdings AS

Prokaryotics Inc

Sichuan Saizhuo Pharmaceutical Co Ltd

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued
Products

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product

Development Milestones

Featured News & Press Releases

Apr 20, 2018: Basilea reports presentations of ceftobiprole data at European Congress
of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 12, 2018: Cardiome Presents Zevtera Abstracts at ECCMID 2018

Mar 22, 2018: Sichuan Saizhuo Pharmaceutical obtained the clinical approval for a new drug "Ristazolone Dry Suspension"

Apr 21, 2017: Basilea announces agreement with FDA on Special Protocol

Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Plc, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by HyPharm GmbH, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by LegoChem Biosciences Inc, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Naicons Srl, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Pharma Holdings AS, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Prokaryotics Inc, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sichuan Saizhuo Pharmaceutical Co Ltd, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, 2022

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/M52D4463D1B6EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M52D4463D1B6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

